News
WADA 2027 Prohibited List: What Changes for SARMs, Peptides and PCT Drugs
WADA's 2027 Prohibited List, valid from 1 January 2027, names peptides in S0, adds SLU-PP-332, SLU-PP-915 and seladelpar as metabolic modulators, and adds imlunestrant…
Topic
News
Regulatory and research news on SARMs, MK-677, peptides and PCT, with sources. 4 guides, each with its sources.
Start with these
News
Enobosarm (Ostarine) Plus Wegovy: Phase 2b PLATEAU Trial Fully Enrolled, Results Due in 2027
On 27 July 2026, Veru said its Phase 2b PLATEAU trial of enobosarm (ostarine) 3 mg with semaglutide had completed enrollment of about 200…
News
FDA Advisers Back Compounding of BPC-157, TB-500, MOTS-c and Three Other Peptides (July 2026)
An FDA advisory committee voted 8–6 to back compounding of BPC-157, KPV and TB-500 and 7–5 for MOTS-c, overriding FDA staff. The vote is…
All guides
News
WADA 2027 Prohibited List: What Changes for SARMs, Peptides and PCT Drugs
WADA's 2027 Prohibited List, valid from 1 January 2027, names peptides in S0, adds SLU-PP-332, SLU-PP-915 and seladelpar as metabolic modulators, and adds imlunestrant…
News
Enobosarm (Ostarine) Plus Wegovy: Phase 2b PLATEAU Trial Fully Enrolled, Results Due in 2027
On 27 July 2026, Veru said its Phase 2b PLATEAU trial of enobosarm (ostarine) 3 mg with semaglutide had completed enrollment of about 200…
News
FDA Advisers Back Compounding of BPC-157, TB-500, MOTS-c and Three Other Peptides (July 2026)
An FDA advisory committee voted 8–6 to back compounding of BPC-157, KPV and TB-500 and 7–5 for MOTS-c, overriding FDA staff. The vote is…
News
FDA Warning Letter: Ostarine, MK-677, Cardarine and LGD-4033 Products Are “Unapproved New Drugs” (December 2025)
In a 12 December 2025 warning letter, the FDA said products sold online as Ostarine MK-2866, MK-677, Cardarine GW501516 and LGD-4033 are unapproved new…